| Name | Title | Contact Details |
|---|
ICON Laboratories is a Farmingdale, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Amlan International is the animal health business of Oil-Dri® Corporation of America, a leader in sorbent mineral technology. Amlan leverages Oil-Dri`s 80-plus years of mineral science expertise to develop proprietary, mineral-based feed additives that support optimal intestinal health while adding value for animal protein producers. The core of our feed additives is our natural mineral ingredient that contains high-capacity opal-CT lepispheres and undergoes proprietary thermal processing specifically tailored for each product. We also create synergistic blends of our mineral with other feed ingredients that further support normal gut function and digestive processes. Oil-Dri and the single-source mineral used in Amlan products are based in the USA, and because Amlan and Oil-Dri are vertically integrated, we control the quality, reliability, and safety of the mineral — from mine to feed bag. We do this by following sustainable mining practices and through the use of natural ingredients in our products. Our mineral-based feed additives meet the demands for cleaner food while reducing the inputs needed to raise production animals, helping to decrease the cost and environmental impact of poultry and livestock production. Leading integrators and producers worldwide trust our products to support animal intestinal health and add value to their operations. You can, too.
Dendreon is a biotechnology company with a singular mission: to harness the power of the body`s immune system to safely improve and extend the lives of people battling cancer. Dendreon`s PROVENGE® (sipuleucel-T), which was approved by the U.S. Food and Drug Administration in April 2010, is the only cellular immunotherapy cancer treatment available. Dendreon is working to expand the application of its technology to discover, develop, manufacture and market additional product candidates for a variety of cancers in the future. Dendreon headquarters are in in Seal Beach, California.
MEI Pharma (Nasdaq: MEIP) is a San Diego-based pharmaceutical company focused on leveraging its extensive development and oncology expertise to identify and advance new therapies for cancer. Our approach to building our pipeline is to license promising cancer agents and create value in programs through development and commercialization, or strategic partnerships, as appropriate. Our portfolio contains four clinical-stage drug candidates, including one candidate in an ongoing global registration trial and another candidate that is anticipated to advance into a registration trial this year. Our drug candidate pipeline includes: Pracinostat, an oral HDAC inhibitor that is in a Phase 3 pivotal study in combination with azacitidine for the treatment of acute myeloid leukemia. Pracinostat is also being evaluated in a clinical study in patients with myelodysplastic syndrome. Pracinostat is licensed to Helsinn Healthcare SA, a Swiss pharmaceutical corporation. ME-401, a selective oral inhibitor of phosphatidylinositol 3-kinase (“PI3K”) delta. ME-401 is anticipated to progress into a single-agent registration study in 2018 for the treatment of adults with relapsed or refractory follicular lymphoma. Voruciclib, an orally administered and selective cyclin-dependent kinase (“CDK”) inhibitor differentiated by its potent in vitro inhibition of CDK9 in addition to CDK6, 4 and 1. Initiation of a Phase I dose-escalation study in patients with relapsed and/or refractory B-cell malignancies after failure of prior standard therapies is scheduled to being in the second calendar quarter of 2018. ME-344, a novel and tumor selective, isoflavone-derived mitochondrial inhibitor drug candidate, has demonstrated evidence of single-agent activity against refractory solid tumors in a Phase I study. In preclinical studies, tumor cells treated with ME-344 resulted in a rapid loss of ATP and cancer cell death. It is currently being evaluated in an investigator-initiated study in combination with the VEGF inhibitor bevacizumab (marketed as Avastin®) in patients with HER2 negative breast cancer.
Goldfinch Bio is a biotechnology company that is singularly focused on discovering and developing precision therapies for kidney disease. Just as the goldfinch was a prominent figure of the Renaissance, Goldfinch Bio is leading a new age of therapeutic discovery to transform the treatment paradigm for patients with kidney disease. Goldfinch is integrating breakthroughs in kidney genetics and biology to identify new therapeutic targets and advance first-in-class drug candidates to treat patients with kidney disease. Our Product Engine will industrialize the integration of genetics and kidney biology and confer a differentiated ability to identify, validate, and pursue novel therapeutic targets to treat progressive kidney disease. At Goldfinch, we`re pioneering a new approach to discover and develop therapeutics that target the molecular basis of kidney disease. We`re looking for teammates who relish the challenge, and are compelled to leave a positive mark on the lives of colleagues and patients alike.